Wall Street brokerages forecast that Oragenics, Inc. (NASDAQ:OGEN) will announce ($0.09) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Oragenics’ earnings. Oragenics reported earnings of ($0.10) per share during the same quarter last year, which suggests a positive year over year growth rate of 10%. The firm is expected to report its next quarterly earnings results on Wednesday, August 12th.
According to Zacks, analysts expect that Oragenics will report full-year earnings of ($0.35) per share for the current fiscal year. For the next financial year, analysts forecast that the business will post earnings of ($0.31) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that follow Oragenics.
Oragenics (NASDAQ:OGEN) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03).
Separately, HC Wainwright cut shares of Oragenics from a “buy” rating to a “neutral” rating in a report on Thursday, April 16th.
OGEN stock opened at $1.21 on Thursday. Oragenics has a twelve month low of $0.35 and a twelve month high of $2.09. The company’s 50 day moving average is $0.84 and its two-hundred day moving average is $0.62.
Oragenics Company Profile
Oragenics, Inc develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients.
Featured Article: Cash Flow Analysis in Stock Selection
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.